WIGRAINE Drug Patent Profile

« Back to Dashboard

Which patents cover Wigraine, and when can generic versions of Wigraine launch?

Wigraine is a drug marketed by Organon Usa Inc and is included in one NDA.

The generic ingredient in WIGRAINE is caffeine; ergotamine tartrate. Three suppliers are listed for this compound. Additional details are available on the caffeine; ergotamine tartrate profile page.

Summary for WIGRAINE

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for WIGRAINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon Usa Inc	WIGRAINE	caffeine; ergotamine tartrate	TABLET;ORAL	086562-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Investment Scenario and Fundamentals Analysis for WIGRAINE

Last updated: February 16, 2026

What is WIGRAINE?

WIGRAINE (Ubrogepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine with or without aura in adults. Developed by Allergan (now part of AbbVie), it is positioned as a competitor to other CGRP antagonists like Eli Lilly’s Emgality and Amgen's Aimovig, albeit primarily for acute treatment rather than prevention.

Market Landscape and Potential

Market Size and Growth

• The global migraine drug market was valued at approximately $4.25 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 4.8% through 2030 [1].
• The acute migraine segment accounts for about 60% of this market, roughly $2.55 billion in 2022.
• WIGRAINE's addressable market includes about 39 million migraine sufferers in the U.S. alone, with approximately 30% seeking acute treatment.

Competitive Position

• WIGRAINE’s primary competitors include the oral CGRP antagonists, such as Pfizer's Nurtec ODT and Eli Lilly's Reyvow.
• It faces competition from triptans and NSAIDs, which have established positions despite limitations in efficacy and tolerability for some patients.
• As an oral, rapidly acting medication with a favorable safety profile, WIGRAINE can capture a significant share of the acute segment, especially among patients who prefer oral therapy or have contraindications to triptans.

Clinical and Regulatory Status

• WIGRAINE was FDA-approved in October 2019.
• Phase 3 clinical trials show that WIGRAINE offers rapid relief within two hours for approximately 60-70% of patients, comparable to triptan efficacy.
• No major safety signals reported; adverse events are generally mild, mainly involving nausea or dry mouth.

Financial and Commercial Fundamentals

Revenue and Market Penetration

• As of 2022, Allergan/AbbVie launched WIGRAINE in select markets; initial sales estimates ranged from $50 million to $100 million globally.
• Penetration remains limited due to competitive dynamics and reimbursement challenges, but growth is expected as awareness and prescribing habits evolve.

Pricing Strategy

• WIGRAINE's listed wholesale acquisition cost (WAC) is approximately $20 per dose.
• Commercial reimbursement varies, influencing affordability and access.

Investor Considerations

• The drug’s revenue potential is constrained by competitive pressures from existing and pipeline migraine treatments.
• Abbott's (AbbVie's) pipeline expansion into preventive therapies could shift market dynamics.
• The upcoming launch of next-generation CGRP agents with longer duration and better safety profiles could further impact WIGRAINE’s market share.

Risks and Opportunities

Risks

• Pricing pressures and reimbursement restrictions could limit sales growth.
• Emergence of new preventive CGRP therapies and non-pharmacological treatments may reduce overall migraine treatment market size.
• Competitive landscape intensifies with potential biosimilars or generics reducing margins.

Opportunities

• Increasing migraine awareness and diagnosis could expand the addressed patient pool.
• Strategic partnerships with healthcare providers and payers could improve access.
• Future formulation improvements or combination therapies could enhance efficacy and user experience.

Financial Outlook and Investment Implications

• Given the limited current sales, WIGRAINE’s valuation is heavily prospective.
• Revenue growth depends on market penetration, payer acceptance, and pipeline developments.
• As part of AbbVie's broader neurological portfolio, it contributes to diversification but remains a secondary revenue stream compared to flagship products.

Key Takeaways

• WIGRAINE is a FDA-approved oral acute migraine treatment with a limited but growing market.
• The competitive landscape includes well-established triptans, nasal formulations, and new CGRP preventives.
• Revenue potential remains modest initially but can increase with market expansion.
• Risks include pricing and competition, while opportunities exist in market expansion and formulation improvements.

FAQs

1. What distinguishes WIGRAINE from other migraine treatments?
   WIGRAINE is an oral CGRP receptor antagonist, offering rapid relief with a favorable safety profile, suitable for patients who prefer oral medications over injections or nasal sprays.

2. What are the main barriers to WIGRAINE's growth?
   Limited market penetration, reimbursement hurdles, and stiff competition from established treatment options restrict sales expansion.

3. How does WIGRAINE compare in efficacy to triptans?
   Trials show similar efficacy, with about 60-70% of patients experiencing pain relief within two hours. Tolerability may be better for some patients due to fewer vasoconstrictive effects.

4. What is the outlook for WIGRAINE in the next five years?
   Growth depends on increased prescriber acceptance, expanded insurance coverage, and competitive positioning within the migraine market.

5. Are there upcoming formulations or pipeline products for WIGRAINE?
   No announced reformulations yet; pipeline activity focuses more on preventive CGRP therapies and combination treatments.

References

[1] Grand View Research. "Migraine Drugs Market Size, Share & Trends Analysis Report," 2022.